UroGen Pharma Ltd. Sublease Income
UroGen Pharma Ltd. (URGN) reported Sublease Income of $0 for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-02.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:SubleaseIncome · last filed 2026-03-02
- UroGen Pharma Ltd. sublease income for the quarter ending 2025-12-31 was $0.00.
- UroGen Pharma Ltd. sublease income for the quarter ending 2025-09-30 was $0.00.
- UroGen Pharma Ltd. sublease income for the quarter ending 2025-06-30 was $0.00.
- UroGen Pharma Ltd. sublease income for the quarter ending 2025-03-31 was $0.00, a 100.00% decline year-over-year.
- UroGen Pharma Ltd. sublease income for fiscal 2025 was $0.00, a 100.00% decline from fiscal 2024.
- UroGen Pharma Ltd. sublease income for fiscal 2024 was $42.00K, a 81.25% decline from fiscal 2023.
- UroGen Pharma Ltd. sublease income for fiscal 2023 was $224.00K, a 0.00% change from fiscal 2022.
- UroGen Pharma Ltd. sublease income for fiscal 2022 was $224.00K, a 0.00% change from fiscal 2021.
| Period end | Sublease Income 3 month | Sublease Income 6 month | Sublease Income 9 month | Sublease Income 12 month |
|---|---|---|---|---|
| 2025-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | $0.00 derived: sum of 2 quarters · filed 2026-03-02 | $0.00 derived: sum of 3 quarters · filed 2026-03-02 | $0.00 10-K · filed 2026-03-02 |
| 2025-09-30 | $0.00 10-Q · filed 2025-11-06 | $0.00 derived: sum of 2 quarters · filed 2025-11-06 | $0.00 10-Q · filed 2025-11-06 | $0.00 derived: sum of 4 quarters · filed 2026-03-02 |
| 2025-06-30 | $0.00 10-Q · filed 2025-08-07 | $0.00 10-Q · filed 2025-08-07 | $0.00 derived: sum of 3 quarters · filed 2026-03-02 | $0.00 derived: sum of 4 quarters · filed 2026-03-02 |
| 2025-03-31 | $0.00 10-Q · filed 2025-05-12 | $0.00 derived: sum of 2 quarters · filed 2026-03-02 | $0.00 derived: sum of 3 quarters · filed 2026-03-02 | $0.00 derived: sum of 4 quarters · filed 2026-03-02 |
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | $0.00 derived: sum of 2 quarters · filed 2026-03-02 | $0.00 derived: sum of 3 quarters · filed 2026-03-02 | $42.00K 10-K · filed 2026-03-02 |
| 2024-09-30 | $0.00 10-Q · filed 2025-11-06 | $0.00 derived: sum of 2 quarters · filed 2025-11-06 | $42.00K 10-Q · filed 2025-11-06 | $98.00K derived: sum of 4 quarters · filed 2025-11-06 |
| 2024-06-30 | $0.00 10-Q · filed 2025-08-07 | $42.00K 10-Q · filed 2025-08-07 | $98.00K derived: sum of 3 quarters · filed 2025-08-07 | $154.00K derived: sum of 4 quarters · filed 2025-08-07 |
| 2024-03-31 | $42.00K 10-Q · filed 2025-05-12 | $98.00K derived: sum of 2 quarters · filed 2025-05-12 | $154.00K derived: sum of 3 quarters · filed 2025-05-12 | $210.00K derived: sum of 4 quarters · filed 2025-05-12 |
| 2023-12-31 | $56.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-10 | $112.00K derived: sum of 2 quarters · filed 2025-03-10 | $168.00K derived: sum of 3 quarters · filed 2025-03-10 | $224.00K 10-K · filed 2025-03-10 |
| 2023-09-30 | $56.00K 10-Q · filed 2024-11-06 | $112.00K derived: sum of 2 quarters · filed 2024-11-06 | $168.00K 10-Q · filed 2024-11-06 | $224.00K derived: sum of 4 quarters · filed 2024-11-06 |
| 2023-06-30 | $56.00K 10-Q · filed 2024-08-13 | $112.00K 10-Q · filed 2024-08-13 | $168.00K derived: sum of 3 quarters · filed 2024-08-13 | $224.00K derived: sum of 4 quarters · filed 2024-08-13 |
| 2023-03-31 | $56.00K 10-Q · filed 2024-05-13 | $112.00K derived: sum of 2 quarters · filed 2024-05-13 | $168.00K derived: sum of 3 quarters · filed 2024-05-13 | $224.00K derived: sum of 4 quarters · filed 2024-05-13 |
| 2022-12-31 | $56.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-14 | $112.00K derived: sum of 2 quarters · filed 2024-03-14 | $168.00K derived: sum of 3 quarters · filed 2024-03-14 | $224.00K 10-K · filed 2024-03-14 |
| 2022-09-30 | $56.00K 10-Q · filed 2023-11-14 | $112.00K derived: sum of 2 quarters · filed 2023-11-14 | $168.00K 10-Q · filed 2023-11-14 | $224.00K derived: sum of 4 quarters · filed 2023-11-14 |
| 2022-06-30 | $56.00K 10-Q · filed 2023-08-10 | $112.00K 10-Q · filed 2023-08-10 | $168.00K derived: sum of 3 quarters · filed 2023-08-10 | $224.00K derived: sum of 4 quarters · filed 2023-08-10 |
| 2022-03-31 | $56.00K 10-Q · filed 2023-05-11 | $112.00K derived: sum of 2 quarters · filed 2023-05-11 | $168.00K derived: sum of 3 quarters · filed 2023-05-11 | $224.00K derived: sum of 4 quarters · filed 2023-05-11 |
| 2021-12-31 | $56.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-24 | $112.00K derived: sum of 2 quarters · filed 2023-03-24 | $168.00K derived: sum of 3 quarters · filed 2023-03-24 | $224.00K 10-K · filed 2023-03-24 |
| 2021-09-30 | $56.00K 10-Q · filed 2022-11-10 | $112.00K derived: sum of 2 quarters · filed 2022-11-10 | $168.00K 10-Q · filed 2022-11-10 | $224.00K derived: sum of 4 quarters · filed 2022-11-10 |
| 2021-06-30 | $56.00K 10-Q · filed 2022-08-11 | $112.00K 10-Q · filed 2022-08-11 | $168.00K derived: sum of 3 quarters · filed 2022-08-11 | $224.00K derived: sum of 4 quarters · filed 2022-08-11 |
| 2021-03-31 | $56.00K 10-Q · filed 2022-05-10 | $112.00K derived: sum of 2 quarters · filed 2022-05-10 | $168.00K derived: sum of 3 quarters · filed 2022-05-10 | $224.00K derived: sum of 4 quarters · filed 2022-05-10 |
| 2020-12-31 | $56.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-21 | $112.00K derived: sum of 2 quarters · filed 2022-03-21 | $168.00K derived: sum of 3 quarters · filed 2022-03-21 | $224.00K 10-K · filed 2022-03-21 |
| 2020-09-30 | $56.00K 10-Q · filed 2021-11-15 | $112.00K derived: sum of 2 quarters · filed 2021-11-15 | $168.00K 10-Q · filed 2021-11-15 | |
| 2020-06-30 | $56.00K 10-Q · filed 2021-08-04 | $112.00K 10-Q · filed 2021-08-04 | ||
| 2020-03-31 | $56.00K 10-Q · filed 2020-05-07 | |||
| 2019-12-31 | $19.00K 10-K · filed 2020-03-02 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |
| Sarepta Therapeutics, Inc. (SRPT) | United States | $1.941B | -13.89 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B |